Last reviewed · How we verify

Trazodone + PAP therapy

VA Office of Research and Development · FDA-approved active Small molecule

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that increases serotonin availability, combined with positive airway pressure (PAP) therapy to mechanically maintain open airways during sleep.

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that increases serotonin availability, combined with positive airway pressure (PAP) therapy to mechanically maintain open airways during sleep. Used for Obstructive sleep apnea with comorbid depression or insomnia, Sleep-disordered breathing in patients with major depressive disorder.

At a glance

Generic nameTrazodone + PAP therapy
SponsorVA Office of Research and Development
Drug classSerotonin antagonist and reuptake inhibitor (SARI) + mechanical ventilation device
TargetSerotonin transporter (SERT); serotonin 5-HT2A receptor antagonism
ModalitySmall molecule
Therapeutic areaPsychiatry / Sleep Medicine
PhaseFDA-approved

Mechanism of action

Trazodone blocks serotonin reuptake and antagonizes serotonin 2A receptors, improving mood and sleep quality in patients with depression and insomnia. PAP therapy (CPAP, BiPAP, or APAP) delivers pressurized air to prevent airway collapse during sleep. This combination addresses both the psychiatric and respiratory components of sleep-disordered breathing in patients with comorbid depression and obstructive sleep apnea.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: